

Ashay D Bhatwadekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7271569/publications.pdf>

Version: 2024-02-01

37
papers

1,267
citations

516215

16
h-index

454577

30
g-index

38
all docs

38
docs citations

38
times ranked

1658
citing authors

#	ARTICLE	IF	CITATIONS
1	Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice. <i>Diabetes</i> , 2018, 67, 1867-1879.	0.3	243
2	Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. <i>Journal of Experimental Medicine</i> , 2009, 206, 2897-2906.	4.2	219
3	Activation of the ACE2/Angiotensin-(1 ⁷)/Mas Receptor Axis Enhances the Reparative Function of Dysfunctional Diabetic Endothelial Progenitors. <i>Diabetes</i> , 2013, 62, 1258-1269.	0.3	91
4	Liver X Receptor Modulates Diabetic Retinopathy Outcome in a Mouse Model of Streptozotocin-Induced Diabetes. <i>Diabetes</i> , 2012, 61, 3270-3279.	0.3	62
5	<i>Per2</i> Mutation Recapitulates the Vascular Phenotype of Diabetes in the Retina and Bone Marrow. <i>Diabetes</i> , 2013, 62, 273-282.	0.3	61
6	Advanced Glycation of Fibronectin Impairs Vascular Repair by Endothelial Progenitor Cells: Implications for Vasodegeneration in Diabetic Retinopathy. , 2008, 49, 1232.		58
7	CNS Inflammation and Bone Marrow Neuropathy in Type 1 Diabetes. <i>American Journal of Pathology</i> , 2013, 183, 1608-1620.	1.9	53
8	Bone marrow-CNS connections: Implications in the pathogenesis of diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2012, 31, 481-494.	7.3	50
9	Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 1367-1378.	1.3	39
10	Transient Inhibition of Transforming Growth Factor- β 21 in Human Diabetic CD34+ Cells Enhances Vascular Reparative Functions. <i>Diabetes</i> , 2010, 59, 2010-2019.	0.3	35
11	Conditional Deletion of <i>Bmal1</i> Accentuates Microvascular and Macrovascular Injury. <i>American Journal of Pathology</i> , 2017, 187, 1426-1435.	1.9	34
12	Anti-integrin therapy for retinovascular diseases. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 935-945.	1.9	32
13	miR-92a Corrects CD34+ Cell Dysfunction in Diabetes by Modulating Core Circadian Genes Involved in Progenitor Differentiation. <i>Diabetes</i> , 2015, 64, 4226-4237.	0.3	27
14	Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World. <i>Genes</i> , 2021, 12, 1200.	1.0	25
15	Metformin Corrects Abnormal Circadian Rhythm and Kir4.1 Channels in Diabetes. , 2020, 61, 46.		23
16	Hematopoietic stem/progenitor involvement in retinal microvascular repair during diabetes: Implications for bone marrow rejuvenation. <i>Vision Research</i> , 2017, 139, 211-220.	0.7	21
17	Retinal Endothelial Cell Apoptosis Stimulates Recruitment of Endothelial Progenitor Cells. , 2009, 50, 4967.		20
18	Advanced glycation end (AGE) product modification of laminin downregulates Kir4.1 in retinal Müller cells. <i>PLoS ONE</i> , 2018, 13, e0193280.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 237-244.	1.9	17
20	Advanced glycation of the Arg-Gly-Asp (RGD) tripeptide motif modulates retinal microvascular endothelial cell dysfunction. <i>Molecular Vision</i> , 2009, 15, 1509-20.	1.1	17
21	Tumor Necrosis Factor Alpha (TNF- α) Disrupts Kir4.1 Channel Expression Resulting in M μ ller Cell Dysfunction in the Retina. , 2017, 58, 2473.		16
22	RNA therapeutics for retinal diseases. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 603-613.	1.4	15
23	Per2-Mediated Vascular Dysfunction Is Caused by the Upregulation of the Connective Tissue Growth Factor (CTGF). <i>PLoS ONE</i> , 2016, 11, e0163367.	1.1	12
24	Ataxia Telangiectasia Mutated Dysregulation Results in Diabetic Retinopathy. <i>Stem Cells</i> , 2016, 34, 405-417.	1.4	12
25	The Diurnal Rhythm of Insulin Receptor Substrate-1 (IRS-1) and Kir4.1 in Diabetes: Implications for a Clock Gene <i>Bmal1</i> . , 2019, 60, 1928.		12
26	Enhancing the Function of CD34+ Cells by Targeting Plasminogen Activator Inhibitor-1. <i>PLoS ONE</i> , 2013, 8, e79067.	1.1	12
27	Promise of endothelial progenitor cell for treatment of diabetic retinopathy. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 29-37.	1.2	8
28	Circadian rhythms in diabetic retinopathy: an overview of pathogenesis and investigational drugs. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1431-1442.	1.9	8
29	AGE and RAGE inhibitors in the treatment of diabetic retinopathy. <i>Expert Review of Ophthalmology</i> , 2007, 2, 105-120.	0.3	7
30	Effect of the pharmacist-managed cardiovascular risk reduction services on diabetic retinopathy outcome measures. <i>Pharmacy Practice</i> , 2019, 17, 1319.	0.8	6
31	Differential Expression of Transforming Growth Factor Beta Receptor 2 (TGF β 2R2) In Diabetic CD34+ Cells: Implications for Vascular Repair. <i>Blood</i> , 2010, 116, 4795-4795.	0.6	4
32	Retinal Phenotyping of Ferrochelatase Mutant Mice Reveals Protoporphyrin Accumulation and Reduced Neovascular Response. , 2021, 62, 36.		3
33	Diabetes Alters Diurnal Rhythm of Electroretinogram in db/db Mice. <i>Yale Journal of Biology and Medicine</i> , 2019, 92, 155-167.	0.2	3
34	Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002801.	1.2	3
35	Inhibition of Plasminogen Activator Inhibitor (PAI)-1 Corrects Diabetic CD34+ Dysfunction.. <i>Blood</i> , 2010, 116, 1601-1601.	0.6	1
36	Circadian rhythm disruption results in visual dysfunction. <i>FASEB BioAdvances</i> , 2022, 4, 364-378.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Hypermethylation of miRNA-17-92 cluster in peripheral blood mononuclear cells in diabetic retinopathy. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102390.	1.8	0